Nevirapine or Efavirenz Combined with Two Nucleoside Reverse Transcriptase Inhibitors Compared to HAART: A Meta-Analysis of Randomized Clinical Trials

REFERENCES

• Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853–860.
   PubMed Web of Science ®Google Scholar
• Hogg RS, O'Shaughnessy MV, Gataric N, et al. Decline in deaths from AIDS due to new antiretrovirals. Lancet. 1997;349:1294.
   PubMed Web of Science ®Google Scholar
• Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA. 1998;279:450–454.
   PubMed Web of Science ®Google Scholar
• Sendi PP, Bucher HC, Craig BA, Pfluger D, Battegay M. Estimating AIDS-free survival in a severely immunosup-pressed asymptomatic HIV-infected population in the era of antiretroviral triple combination therapy. Swiss HIV Co-hort Study. J Acquir Immune Defic Syndr Hum RetroviroL 1999;20:376–381.
   PubMedGoogle Scholar
• Cameron DW, Heath-Chiozzi M, Danner S, et al. Randomised placebo-controlled trial of ritonavir in ad-vanced HIV-1 disease. Lancet. 1998;351:543–549.
   PubMed Web of Science ®Google Scholar
• Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997;337:725–733.
   PubMed Web of Science ®Google Scholar
• Pocock SJ. Clinical Trials: A Practical Approach. New York: Wiley; 1983.
   Google Scholar
• Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta block-ade during and after myocardial infarction: An overview of the randomized trials. Prog Cardiovasc Dis. 1985;27:335–371.
   PubMed Web of Science ®Google Scholar
• Mantel N, Haenzel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–748.
   PubMed Web of Science ®Google Scholar
• D'Aquila RT, Hughes MD, Johnson VA, et al. Nevirapine, zidovudine and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1996;124:1019–1030.
   PubMed Web of Science ®Google Scholar
• Henry K, Erice A, Tierney C, et al. A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. J Acquir Immune Defic Syndr Hum RetroviroL 1998;19:339–349.
   PubMedGoogle Scholar
• Montaner JSG, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients. The INCAS trial. JAMA. 1998;279:930–937.
   PubMed Web of Science ®Google Scholar
• Haas D, Seekins D, Cooper R, et al. A phase II, double-blind, placebo-controlled, dose ranging study to assess the antiretroviral activity and safety of efavirenz (EFV, SUSTIVA, DMP 266) in combination with open-label zidovudine with lamivudine at 36 weeks. Presented at: XIII International Conference on AIDS; July 1998; Geneva. Ab-stract 22334.
   Google Scholar
• Mayers D, Jemsek J, Eyster E, Tashima K, Thompson M, Ruiz N. A double-blind, placebo-controlled study to assess the safety, tolerability and antiretroviral activity of efavirenz (EFV, Sustiva, DMP 266) in combination with open-label zidovudine and lamivudine in HIV-1 infected patients. Pre-sented at: XIII International Conference on AIDS; 1998; Geneva. Abstract 22340.
   Google Scholar
• Floridia M, Bucciardini R, Ricciardulli D, et al. A random-ized, double-blind trial on the use of a triple combination including nevirapine, a nonnucleoside reverse tran-scriptase HIV inhibitor, in antiretroviral-naive patients with advanced disease. J Acquir Immune Defic Syndr Hum RetroviroL 1999;20:11–19.
   PubMedGoogle Scholar
• Albrecht M, Katzenstein D, Bosch R, Liou S, Hammer S. ACTG 364: Virologic efficacy of nelfinavir and/or efavirenz in combination with new nucleoside analogs in nucleoside experienced subjects. Presented at: Sixth Conference on Retroviruses and Opportunistic Infections; 1999; Chicago. Abstract 489.
   Google Scholar
• Murphy RL, Katlama C, Johnson V, et al. The Atlantic Study: A randomized, open-label trial comparing two pro-tease inhibitor (PI)-sparing antiretroviral strategies versus a standard P1-containing regimen. 48 weeks data. Presented at: 39th Interscience Conference on Antimicrobial Agents Chemotherapy; 1999; San Francisco. Abstract LB–22.
   Google Scholar
• Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med. 1999;341:1865–1873.
   PubMed Web of Science ®Google Scholar
• Podzamczer D, Ferrer E, Consiglio E, et al. Preliminary results of a randomized multicenter study comparing Combivir (ZDV/3TC) plus nelfinavir or nevirapine in HIV-infected naive patients (COMBINE study). Presented at: Seventh Conference on Retroviruses and Opportunistic Infections; 2000; San Francisco. Abstract 510.
   Google Scholar
• Ruiz L, Negredo E, Domingo P, et al. Clinical, virological and immunological benefit of switching the protease inhibi-tor by nevirapine in HAART-experienced patients suffering lipodystrophy: 36-week follow-up. Presented at: Seventh Conference on Retroviruses and Opportunistic Infections; 2000; San Francisco. Abstract 206.
   Google Scholar
• Carpenter CCJ, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults. Updated recommendations of the Inter-national AIDS Society - USA Panel. JAMA. 2000;283:381–390.
   PubMed Web of Science ®Google Scholar
• Moyle GJ. Efavirenz: Shifting the HAART paradigm in adult HIV-1 infection. Exp Opin Invest Drugs. 1999;8:473–486.
   PubMedGoogle Scholar
• Mellors JW, Kingsley LA, Rinaldo CR, et al. Quantitation of HIV-RNA in plasma predicts outcome after seroconversion. Ann Intern Med. 1995;122:573–579.
   PubMed Web of Science ®Google Scholar
• Marschner IC, Collier AC, Coombs RW, et al. Use of changes in plasma levels of human immunodeficiency vi-rus type 1 RNA to assess the clinical benefit of antiretroviral therapy. J Infect Dis. 1998;177:40–47.
   PubMed Web of Science ®Google Scholar
• Eron JJ Jr. The treatment of antiretroviral-naive subjects with the 3TC/zidovudine combination: A review of North American (NUCA 3001) and European (NUCB 3001) trials. AIDS. 1996;10:S11–519.
   PubMed Web of Science ®Google Scholar
• Staszewski S, Hill AM, Bartlett J, et al. Reduction in HIV-1 disease progression for zidovudine/lamivudine relative to control treatments: A meta-analysis of controlled trials. AIDS. 1997;11:477–483.
   PubMed Web of Science ®Google Scholar
• Brun-Vezinet F, Boucher C, Loveday C, et al. HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. The National Virology Groups. Delta Virology Working Group and Coordinating Committee. Lancet. 1997;350:983–990.
   PubMed Web of Science ®Google Scholar
• Moss AR, Bacchetti P. Natural history of HIV infection. AIDS. 1989;3:55.
   PubMed Web of Science ®Google Scholar
• Fischl MA, Richman DD, Hansen N, et al. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trial Group. Ann Intern Med. 1990;112:727–737.
   PubMed Web of Science ®Google Scholar
• HIV Trialists Collaborative Group. Zidovudine, didanosine and zalcitabine in the treatment of HIV infection: Meta-analyses of the randomised evidence. Lancet. 1999;353:2014–2025.
   PubMed Web of Science ®Google Scholar